Fast Food Stock Flashing Surefire Bull Signal
The shares of Yum! Brands Inc (NYSE:YUM) are up 0.8% to trade at $145.07 at last glance while sporting an 8.7% year-to-date lead. Pressure at the 20-day moving average is keeping a lid on today's gains, while the $153 region has acted as a ceiling since the stock's April 4 bear gap of 8.4%. The shares are now trading within striking distance of a historically bullish trendline, however, which may help it close that bear gap.
Per Schaeffer's Senior Quantitative Analyst Rocky White, the security is within one standard deviation of its 126-day moving average (representing half a year of trading). YUM was above this this trendline in at least eight of the last 10 trading days and spent 80% of the last two months above it. Within these parameters, five other signals occurred in the past five years, after which the equity was higher one month later every time, averaging a 3.9% pop. A move of comparable magnitude would place YUM back above $150.
A round of bull notes could create tailwinds and help get YUM the rest of the way through overhead pressure at $140. Of the 27 analysts in coverage, 20 still call the equity a tepid "hold" rating.
Options are looking affordable as well, per the stock's Schaeffer's Volatility Index (SVI) of 18%, which ranks in the 12th percentile of its annual range. This means options traders are pricing in low volatility expectations. YUM has also tended to outperform these expectations, per its of 83 out of 100.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Is AbbVie the Best Dividend Stock in Big Pharma Today?
AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, having raised its dividend for 52 straight years. That kind of track record makes a dividend cut highly unlikely, as it would break the streak and potentially take decades to regain entry into this elite group. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) is a leading pharmaceutical company with a strong product lineup that consistently delivers solid revenue and earnings. Its top growth drivers, Skyrizi and Rinvoq, have outperformed expectations, leading management to raise their combined 2027 sales forecast to over $31 billion. The company also benefits from other key products like Botox and a deep pipeline of new therapies to offset future patent expirations. With strong cash flow and a reliable portfolio, AbbVie Inc. (NYSE:ABBV) remains an attractive pick for income investors looking for long-term dividend stability. Naturally, if AbbVie encounters serious challenges, it could be pressured to reduce its dividend. One concern is its elevated payout ratio, currently at 267.66%. Typically, when a company's payout ratio remains above 70% for an extended time, it raises the risk of a dividend cut or suspension. However, AbbVie Inc. (NYSE:ABBV)'s next-generation immunology drugs are seeing strong growth, which could help offset the challenges it's facing from Humira. The rheumatoid arthritis treatment has been under pressure due to its loss of market exclusivity in the US and the increasing competition from biosimilars. ABBV currently offers a dividend yield of 3.5%, which is above S&P's average dividend yield of 1.3%. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Citi Increases PT on Oracle (ORCL), Keeps Neutral
Oracle Corporation (NYSE:ORCL) is one of the 10 software stocks analysts are upgrading. On June 12, Citi raised the price target on the company's stock to $196 from $186, while keeping a 'Neutral' rating. The firm believes that Oracle Corporation (NYSE:ORCL)'s Q4 2025 results are incrementally positive considering fiscal 2026 demand. That being said, the company's near-term earnings and FCF estimates have been falling. A team of IT professionals meticulously crafting a large-scale enterprise performance management system. As per Citi, Oracle Corporation (NYSE:ORCL) posted a strong Q4 2025, while it saw modest bookings growth. However, this was overshadowed by a strong fiscal 2026 sales outlook amidst accelerating cloud, remaining performance obligation, and total revenue growth, added the analyst. Oracle Corporation (NYSE:ORCL) expects its total cloud growth rate, applications plus infrastructure, to increase from 24% in FY 2025 to more than 40% in FY 2026. Notably, the Cloud Infrastructure growth rate is anticipated to increase from 50% in FY 2025 to more than 70% in FY 2026, while RPO is projected to grow over 100% in FY 2026. Also, Oracle Corporation (NYSE:ORCL) anticipates triple-digit MultiCloud revenue growth to continue in FY 2026. Ariel Investments, an investment management company, released its Q1 2025 investor letter. Here is what the fund said: 'Lastly, global leader in enterprise software, Oracle Corporation (NYSE:ORCL), traded lower alongside the broader technology sector due to macroeconomic uncertainty and in particular, the near-term prospects for artificial intelligence investment (AI) spending. As a result, ORCL reported weaker than expected quarterly earnings results. Nonetheless, management expects double-digit growth for fiscal 2026 and 2027, citing significant demand for its cloud and AI capabilities. This supports our view that ORCL's positioning as the leading provider of database software and cloud-based infrastructure is entrenched, making it a key beneficiary of global demand for generative AI development.' While we acknowledge the potential of ORCL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ORCL and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
Yahoo
12 hours ago
- Yahoo
Zeta Global (ZETA) Jumps 12.6% on Untapped AI Opportunities
Zeta Global Holdings Corp. (NYSE:ZETA) is one of the Zeta Global Holdings rallied by 12.63 percent on Friday to end at $14.18 apiece as investors snapped up shares following a study that marketing companies are lagging behind AI execution vis-a-vis its ambitions. In its study called 'It's Time to Get Serious About AI's Business Value,' Zeta Global Holdings Corp. (NYSE:ZETA) said that while many marketing organizations have begun implementing AI, most are still in the early stages of building the data, skills and systems required to scale it effectively and realize its full enterprise potential. Based on a survey of 300 North American marketing technology decision-makers, the study found that 62 percent of organizations described their current AI deployment as 'limited' or 'moderate.' The study was viewed by investors as a huge potential and opportunity for Zeta Global Holdings Corp. (NYSE:ZETA) to tap. 'Marketing should be at the front lines of the AI revolution, but many teams are held back by fragmented data, legacy systems, and skills gaps,' said Chairman and CEO David Steinberg. A marketing manager looking at the data dashboard of a marketing automation software showing successful campaign results. 'This study reinforces what we hear every day: marketers don't need more AI promises; they need practical, scalable ways to turn AI into better performance.' While we acknowledge the potential of ZETA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
